BioSpace News Archive

North American Partners in Anesthesia announced an agreement with Richmond University Medical Center to provide anesthesia services.

Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

BIONIK Laboratories Corp. announced that Richard Russo, Interim CEO, will present a corporate overview at the National Investment Banking Association conference on September 8, 2022.

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced today that John Tucker, president & chief executive officer, is scheduled to present virtually at the H.C. Wainwright 24th Annual Global Investment Conference.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating virtually in the H.C. Wainwright 24th Annual Global Investment Conference.

Merus N.V. (Nasdaq: MRUS), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a panel discussion at Citi’s 17th Annual BioPharma Conference on Thursday, September 8, 2022 at 2:40 p.m. ET.

AVITA Medical, Inc. announced that COSMOTEC, an M3 Group Company, received insurance coverage in Japan for the RECELL® System for the treatment of acute burns.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced a positive safety review of the ongoing INTEGRIS-IPF Phase 2a trial of PLN-74809 at 320 mg once-daily dose in patients with idiopathic pulmonary fibrosis (IPF) from a regularly scheduled meeting of its independent Data Safety Monitoring Board (DSMB).

CCS, a leading provider of clinical programs and home-delivered medical supplies for those living with chronic conditions, announced the addition of Mike Rolla as the company’s Chief Growth Officer.

MC2 Therapeutics A/S, announces breakthrough discovery of a novel biological paradigm applicable for treatment of a number of urea associated skin diseases affecting millions of people globally.